Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Susan K. Lyman"'
Autor:
Susan K. Lyman, Suzanne C. Crawley, Ruoyu Gong, Joanne I. Adamkewicz, Garth McGrath, Jason Y. Chew, Jennifer Choi, Charles R. Holst, Leanne H. Goon, Scott A. Detmer, Jana Vaclavikova, Mary E. Gerritsen, Robert A. Blake
Publikováno v:
PLoS ONE, Vol 6, Iss 3 (2011)
Externí odkaz:
https://doaj.org/article/2f45722322f6416e9d86caf0046a9f63
Autor:
Valentina Boni, Mary J. Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E. Sanborn, Randy F. Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J. Harding, Stella K. Kim, Iris H.C. Miedema, Danielle J. Vugts, Marc C. Huisman, Gerben J.C. Zwezerijnen, Guus A.M.S. van Dongen, C. Willemien Menke van der Houven van Oordt, Song Wang, Tam Dang, Ivan A. Zein, Olga Vasiljeva, Susan K. Lyman, Virginia Paton, Alison Hannah, Joyce F. Liu
Publikováno v:
Clinical Cancer Research, 28(10), 2020-2029. American Association for Cancer Research Inc.
Purpose: Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue an
Autor:
Joyce F. Liu, Alison Hannah, Virginia Paton, Susan K. Lyman, Olga Vasiljeva, Ivan A. Zein, Tam Dang, Song Wang, C. Willemien Menke van der Houven van Oordt, Guus A.M.S. van Dongen, Gerben J.C. Zwezerijnen, Marc C. Huisman, Danielle J. Vugts, Iris H.C. Miedema, Stella K. Kim, James J. Harding, Shadia Jalal, Javier Garcia-Corbacho, Misako Nagasaka, Patricia LoRusso, Randy F. Sweis, Rachel E. Sanborn, Nataliya Uboha, Funda Meric-Bernstam, Alexander Spira, Hendrik-Tobias Arkenau, Mary J. Fidler, Valentina Boni
Supplementary Data from Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20af64024eca128b7e651ebd8e6392cb
https://doi.org/10.1158/1078-0432.22486622
https://doi.org/10.1158/1078-0432.22486622
Autor:
Joyce F. Liu, Alison Hannah, Virginia Paton, Susan K. Lyman, Olga Vasiljeva, Ivan A. Zein, Tam Dang, Song Wang, C. Willemien Menke van der Houven van Oordt, Guus A.M.S. van Dongen, Gerben J.C. Zwezerijnen, Marc C. Huisman, Danielle J. Vugts, Iris H.C. Miedema, Stella K. Kim, James J. Harding, Shadia Jalal, Javier Garcia-Corbacho, Misako Nagasaka, Patricia LoRusso, Randy F. Sweis, Rachel E. Sanborn, Nataliya Uboha, Funda Meric-Bernstam, Alexander Spira, Hendrik-Tobias Arkenau, Mary J. Fidler, Valentina Boni
Purpose:Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87df2ee6ab1f32889e141aee714623c0
https://doi.org/10.1158/1078-0432.c.6532364.v1
https://doi.org/10.1158/1078-0432.c.6532364.v1
Autor:
Mary J. Fidler, Luc Desnoyers, Virginia Paton, Alison L. Hannah, Ivan Adiputra Zein, Tobias Arkenau, Alexander I. Spira, Valentina Boni, Funda Meric-Bernstam, Susan K. Lyman, Tam Dang, Misako Nagasaka, Patricia LoRusso, William M. Kavanaugh, Joyce F. Liu, Nataliya Volodymyrivna Uboha
Publikováno v:
Cancer Research. 81:PS11-07
Background: Probody® therapeutics (Pb-Tx) are masked antibodies designed to be selectively activated in the tumor microenvironment by tumor-associated proteases, while remaining largely inactive in normal tissue and in circulation. This allows Pb-Tx
Autor:
Susan K. Lyman, Bjorn L. Millard, Mark Stroh, Michelle Green, Luc R. Desnoyers, Alison L. Hannah, Hong Lu, W. Michael Kavanaugh, Will Garner, Jennifer Richardson, John M. Burke, Joshua F. Apgar
Publikováno v:
Clinical Pharmacology & Therapeutics. 109:383-393
CX-072 is an anti-PD-L1 (programmed death ligand 1) Probody therapeutic (Pb-Tx) designed to be preferentially activated by proteases in the tumor microenvironment and not in healthy tissue. Here, we report the model-informed drug development of CX-07
Autor:
Derek C Marshall, Susan K Lyman, Scott McCauley, Maria Kovalenko, Rhyannon Spangler, Chian Liu, Michael Lee, Christopher O'Sullivan, Vivian Barry-Hamilton, Haben Ghermazien, Amanda Mikels-Vigdal, Carlos A Garcia, Brett Jorgensen, Arleene C Velayo, Ruth Wang, Joanne I Adamkewicz, Victoria Smith
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0127063 (2015)
Expression of matrix metalloproteinase 9 (MMP9) is elevated in a variety of inflammatory and oncology indications, including ulcerative colitis and colorectal cancer. MMP9 is a downstream effector and an upstream mediator of pathways involved in grow
Externí odkaz:
https://doaj.org/article/8613ab116c9b4cdeac17c58cadfebedf
Autor:
Susan K Lyman, Suzanne C Crawley, Ruoyu Gong, Joanne I Adamkewicz, Garth McGrath, Jason Y Chew, Jennifer Choi, Charles R Holst, Leanne H Goon, Scott A Detmer, Jana Vaclavikova, Mary E Gerritsen, Robert A Blake
Publikováno v:
PLoS ONE, Vol 6, Iss 3, p e17692 (2011)
BackgroundMany proteins that are dysregulated or mutated in cancer cells rely on the molecular chaperone HSP90 for their proper folding and activity, which has led to considerable interest in HSP90 as a cancer drug target. The diverse array of HSP90
Externí odkaz:
https://doaj.org/article/f3255661be8a49999d93ff431dca0903
Autor:
Silvia Racedo, Christopher L. Bowlus, Derek Marshall, Hans Jürgen Gruber, Carolin Lackner, Emmanuel Moreau, Johannes R. Hov, Marion J. Pollheimer, Tor J. Eide, Joanne I. Adamkewicz, Victoria Smith, Amanda Mikels-Vigdal, Tobias Madl, Tom H. Karlsen, Rudolf E. Stauber, Hubert Scharnagl, Peter Fickert, Tatjana Stojakovic, Gernot Zollner, Michael Trauner, Susan K. Lyman
Publikováno v:
Journal of hepatology. 69(2)
Background & Aims The lysyl oxidase-like protein 2 (LOXL2) promotes stabilization of the extracellular matrix, chemotaxis, cell growth and cell mobility. We aimed to (i) identify stimuli of LOXL2 in cholangiopathies, (ii) characterize the effects of
Autor:
Yingze Zhang, Joanne I. Adamkewicz, Lixin Shao, Kathleen O. Lindell, Victoria Smith, Kevin F. Gibson, Thomas G. O'Riordan, Susan K. Lyman, Jason W. Chien, Naftali Kaminski, Thomas J. Richards
Publikováno v:
European Respiratory Journal. 43:1430-1438
We evaluated whether lysyl oxidase-like 2 (LOXL2), which promotes cross-linking of collagen in pathological stroma, was detectable in serum from idiopathic pulmonary fibrosis (IPF) patients, and assessed its relationship with IPF disease progression.